

The Scientific Advisory Board on the IQWiG report:

Rapid-acting Insulin Analogues for the Treatment of Diabetes Mellitus Type 2

The Scientific Advisory Board of the IQWiG met on March 20, 2006 in Frankfurt. Responding to requests by the Director of IQWiG the following comments were given by the Board:

1) The Scientific Advisory Board emphasised that IQWiG reports are produced on the basis of the IQWiG Methods (Version 1.0, published on 1 March 2005 ([www.iqwig.de/über uns](http://www.iqwig.de/über_uns))).

In this document the methods applied by the IQWiG to evaluate clinical studies are outlined in detail. They are subject to regular updates which are published after detailed discussion with the Scientific Advisory Board.

2) The Scientific Advisory Board confirmed that the IQWiG report on 'Rapid-acting Insulin Analogues for the Treatment of Diabetes Mellitus Type 2' was prepared in accordance with the IQWiG Methods that are presently effective.

3) The Scientific Advisory Board is of the opinion that the discussion about the IQWiG Report on 'Rapid-acting Insulin Analogues for the Treatment of Diabetes Mellitus Type 2' should be clearly restricted to the scientific contents and not to potential political implications. The Scientific Advisory Board would appreciate it if all participants in this discussion would adhere to the principles of a decent dispute which include polite manners and abstinence from personal allegations or derogatory language.